ImmunoPrecise Antibodies (IPA) has released an update.
ImmunoPrecise Antibodies has achieved a major breakthrough in developing antibodies for cancer treatment, targeting the TrkB protein often found in aggressive cancers. This advancement not only showcases their innovative AI-driven capabilities but also positions them strategically in a cancer therapy market expected to reach $20.7 billion by 2028. The company’s TATX-112 program has identified promising candidates for further development, potentially enhancing the effectiveness and safety of cancer treatments.
For further insights into IPA stock, check out TipRanks’ Stock Analysis page.
